139 related articles for article (PubMed ID: 36815731)
1. Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy.
Sun M; Liu Z; Wu L; Yang J; Ren J; Qu X
J Am Chem Soc; 2023 Mar; 145(9):5330-5341. PubMed ID: 36815731
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
3. Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies
Xu X; Zheng J; Liang N; Zhang X; Shabiti S; Wang Z; Yu S; Pan ZY; Li W; Cai L
ACS Nano; 2024 Apr; 18(13):9413-9430. PubMed ID: 38522084
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal-Organic Framework Nanoparticles to Boost Cancer Immunotherapy.
Cai Z; Xin F; Wei Z; Wu M; Lin X; Du X; Chen G; Zhang D; Zhang Z; Liu X; Yao C
Adv Healthc Mater; 2020 Jan; 9(1):e1900996. PubMed ID: 31746153
[TBL] [Abstract][Full Text] [Related]
6. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
7. Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy.
Xu W; Pang C; Song C; Qian J; Feola S; Cerullo V; Fan L; Yu H; Lehto VP
Acta Biomater; 2022 Oct; 152():473-483. PubMed ID: 36087872
[TBL] [Abstract][Full Text] [Related]
8. In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy.
Yang W; Zhu G; Wang S; Yu G; Yang Z; Lin L; Zhou Z; Liu Y; Dai Y; Zhang F; Shen Z; Liu Y; He Z; Lau J; Niu G; Kiesewetter DO; Hu S; Chen X
ACS Nano; 2019 Mar; 13(3):3083-3094. PubMed ID: 30835435
[TBL] [Abstract][Full Text] [Related]
9. Injectable thermosensitive hydrogel to enhance the photothermal ablation and systemic immunotherapy of breast tumors.
Qin T; Li R; Jin H; Wang Y; Feng L
Biomater Sci; 2022 Oct; 10(20):6003-6012. PubMed ID: 36053224
[TBL] [Abstract][Full Text] [Related]
10. Hollow Aluminum Hydroxide Modified Silica Nanoadjuvants with Amplified Immunotherapy Effects through Immunogenic Cell Death Induction and Antigen Release.
Tan J; Ding B; Zheng P; Chen H; Ma P; Lin J
Small; 2022 Aug; 18(34):e2202462. PubMed ID: 35896867
[TBL] [Abstract][Full Text] [Related]
11. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D; Wu T; Lan S; Liu C; Guo Z; Zhang W
Biomaterials; 2022 Oct; 289():121808. PubMed ID: 36137415
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccine for the effective immunotherapy of breast cancer.
Ni J; Song J; Wang B; Hua H; Zhu H; Guo X; Xiong S; Zhao Y
Biomed Pharmacother; 2020 Jun; 126():110046. PubMed ID: 32145586
[TBL] [Abstract][Full Text] [Related]
14. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
15. Single-Atom Catalysts Mediated Bioorthogonal Modulation of N
Sun M; Liu X; Liu Z; Zhang W; Li G; Ren J; Qu X
J Am Chem Soc; 2024 Mar; 146(12):8216-8227. PubMed ID: 38486429
[TBL] [Abstract][Full Text] [Related]
16. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
18. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
19. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
